OMC
TPST icon

Old Mission Capital’s Tempest Therapeutics TPST Stock Holding History

Old Mission Capital’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-275
Closed -$94K – 599
2020
Q2 		$94K Buy
+275
New +$110K 0.01% 432

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Old Mission Capital's TPST Position: Q3 2020 in Review

Old Mission Capital sold out of Tempest Therapeutics (TPST) in Q3 2020, closing a stake of 275 shares — an estimated $94K sold.

Old Mission Capital first reported a position in TPST in Q2 2020 and held it in 1 quarter. The position peaked at $94K in Q2 2020. 42 funds tracked by Wall St. Rank hold TPST as of Q3 2020.

  • Old Mission Capital reported no remaining Tempest Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Old Mission Capital sold 275 Tempest Therapeutics shares in Q3 2020, an estimated $94K.
  • Old Mission Capital first reported a position in Tempest Therapeutics in Q2 2020 and held it in 1 quarter.
  • Old Mission Capital's Tempest Therapeutics position peaked at $94K in Q2 2020.
  • 42 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2020.

Based on Old Mission Capital's 13F filing for Q3 2020, filed 16 Nov 2020.